8-K: Artivion Reports Modest Revenue Growth in Q1 2025, Raises Full-Year Outlook

Artivion's Q1 2025 results show a slight revenue increase and a raised full-year revenue outlook despite a net loss, driven by growth in key product lines and recovery from a cybersecurity incident.

Summary

• Artivion reported a 2% increase in revenue on a GAAP basis for Q1 2025, reaching $99.0 million compared to $97.4 million in Q1 2024.
• On a non-GAAP constant currency basis, revenue increased by 4%.
• The company experienced a net loss of $(0.5) million, or $(0.01) per fully diluted share, compared to a net income of $7.5 million, or $0.18 per fully diluted share, in Q1 2024.
• Non-GAAP net income was $2.5 million, or $0.06 per fully diluted share, consistent with the $2.6 million reported in Q1 2024.
• Adjusted EBITDA increased by 1% to $17.5 million.
• The company is raising its full-year 2025 revenue guidance to a range of $423 to $435 million, representing an 11% to 14% growth on a constant currency basis.
• Adjusted EBITDA is expected to grow between 18% and 28% for the full year, resulting in a range of $84 to $91 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company experienced a net loss, it is raising its full-year revenue guidance and showing growth in key product lines. The positive clinical data for NEXUS also contributes to the positive sentiment.

Positives

• Revenue increased by 2% on a GAAP basis and 4% on a non-GAAP constant currency basis.
• Stent grafts, On-X, and BioGlue product lines showed strong growth.
• The company is raising its full-year revenue guidance.
• Positive clinical data was presented for the NEXUS aortic stent graft system.
• The company is making progress in recovering from the cybersecurity incident.

Negatives

• The company reported a net loss of $(0.5) million for the quarter.
• Preservation services revenue decreased by 23% due to the cybersecurity incident.
• The net income was significantly lower than the $7.533 million from the same quarter last year.

Risks

• The company's financial performance is subject to risks including regulatory decisions, international operations, and the impact of the cybersecurity incident.
• The benefits anticipated from acquisitions and clinical trials may not be achieved.
• The company's future performance could differ significantly from management's expectations.

Future Outlook

Artivion expects full-year 2025 revenue to be in the range of $423 to $435 million, representing growth of 11% to 14% on a constant currency basis, and adjusted EBITDA to increase between 18% and 28%, resulting in a range of $84 to $91 million.

Management Comments

• 'I am pleased with our first quarter results as we returned to normal operations following our previously disclosed cybersecurity incident while making substantial progress on our strategic growth initiatives,' said Pat Mackin, Chairman, President, and Chief Executive Officer.
• Mr. Mackin added, 'Given our strong first quarter performance, we are raising the midpoint of our full year revenue expectations for 2025 and remain confident in our ability to grow adjusted EBITDA at twice the rate of constant currency revenue growth.'
• 'With these outcomes, we believe NEXUS remains on track for FDA approval in the second half of 2026 and we look forward to Endospan sharing 1-year follow up data next year,' Mr. Mackin concluded.

Industry Context

Artivion operates in the cardiac and vascular surgery market, competing with companies like Medtronic, Edwards Lifesciences, and Abbott. The growth in stent grafts and heart valves aligns with the increasing demand for minimally invasive cardiac procedures. The cybersecurity incident highlights the growing risk of cyberattacks in the healthcare industry and the importance of robust cybersecurity measures.

Comparison to Industry Standards

• Medtronic, a major player in the medical device industry, reported \$8.5 billion in revenue for its most recent quarter, showcasing the scale of larger competitors.
• Edwards Lifesciences, specializing in heart valves and hemodynamic monitoring, reported \$1.6 billion in sales for 2024, indicating a strong focus on cardiovascular solutions.
• Artivion's growth in stent grafts mirrors trends seen in companies like W.L. Gore & Associates, which also focus on vascular grafts and endovascular solutions.
• The 63% reduction in major adverse events (MAE) in the NEXUS TRIOMPHE IDE trial is a significant achievement, potentially positioning it favorably against existing aortic stent graft systems from competitors.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the raised revenue guidance.
• Employees may be affected by the ongoing recovery from the cybersecurity incident.
• Customers will benefit from the continued development of innovative products like NEXUS and AMDS.

Next Steps

• Endospan will share 1-year follow up data next year.
• The company will continue to work towards FDA approval for NEXUS in the second half of 2026.

Key Dates

Keywords

Artivion, financial results, revenue, EBITDA, stent grafts, On-X, BioGlue, cybersecurity, NEXUS, AMDS, FDA, cardiac surgery, vascular surgery, aortic disease